Novel standards and emerging therapies for systemically treatment-na?ve clear cell renal cell carcinoma - a rapidly changing landscape

• 作者: Ritesh R.Kotecha Martin H.Voss
• 来源期刊: 癌症转移与治疗（英文版）
• 年，卷（期）: 2021,（12）
• 所属期刊栏目: Review
• 页码范围: 44-54
• 页数: 11页
• 语种: 英文
• DOI: 10.20517/2394-4722.2021.163

摘要

The last decade has brought about major advances in systemic therapy for patients with advanced clear cell renal cell carcinoma. The introduction of angiogenesis targeting agents, immune checkpoint inhibitors, and combinations thereof has resulted in a multitude of therapeutic standards for patients with newly diagnosed advanced disease. With the rapid adoption and increasing number of available options for patients, selection amongst treatment regimens has become complex. Further, a new balance is also being sought to optimize treatment outcomes and limit treatment-related toxicities. With a rising bar against which novel therapeutics are being measured, the field looks toward an evolved understanding of tumor biology to help pave new ways forward for individualized therapy. Here, we review pivotal studies that led to regulatory approvals and ongoing clinical trials conducted in patients with systemically untreated clear cell renal cell carcinoma and provide perspective on how newly emerging data can be integrated into this rapidly changing landscape.